What does Cerebras Systems, the first successful waferscale computing commercializer and a contender in the race to provide compute for the world’s burgeoning AI inference workload, do for an encore?

The Powerball jackpot has leaped to $1.10 billion after there were no big grand prize winners in Saturday's drawing. Saturday's winning numbers were 3, 18, 22, 27, 33 with a red Powerball of 17 and a ...

Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, ...

Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum, Università di Bologna, Via P. Gobetti 85, 40129 Bologna, Italy Center for Chemical Catalysis − C 3, Alma Mater Studiorum, Università ...

TOKYO, Aug 7 (Reuters) - Japan's Toyota Motor (7203.T), opens new tab said on Thursday it expected a hit of nearly $10 billion from President Donald Trump's tariffs on cars imported into the United ...

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

The total exercise workload is an important factor influencing immune health. Appropriately prescribed physical activity can mitigate the detrimental effects of chronic inflammation, bolster the ...

Subjective and objective limitations to exercise and activity are hallmarks of heart failure (HF), regardless of underlying ejection fraction (EF). These limitations relate to cardiovascular ...

Clinical guidelines broadly recommend exercise training for patients with heart failure (HF). This review examines clinical benefits of exercise training across HF subtypes, focusing on clinical ...

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, we ...

Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.